Functional Characterization And Therapeutic Targeting Of The Novel Long Noncoding RNA RP1-40E16.9
Funder
National Health and Medical Research Council
Funding Amount
$673,447.00
Summary
Cancer is the most common cause of death from diseases in children. Neuroblastoma is the most common solid tumour in early childhood. In this project, we will define the role of a novel long non-protein-coding RNA in promoting neuroblastoma initiation and progression. We will also define the anti-cancer efficacy of a novel therapy targeting the long non-protein-coding RNA.
Targeting JMJD6 Gene Gain For The Therapy Of Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$381,012.00
Summary
Cancer is the most common cause of death from disease in children. Neuroblastoma is the most prevalent solid tumour in early childhood. In this project, we will define the key role of JMJD6 gene gain in neuroblastoma cell proliferation, survival and tumourigenesis. We will also identify a novel therapeutic strategy for the treatment of neuroblastoma.
New Compounds For Tailored Therapy Against MLL-rearranged Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$326,401.00
Summary
Some of the worst leukaemia survival rates are found in children and adults whose leukaemias display abnormalities of the MLL gene and alternative therapies are therefore urgently required for these patients. The aim of this project is to develop new compounds that specifically inhibit this abnormal gene and in turn inhibit the growth of these cells in the patient. In this way we hope to provide new and more effective therapies for patients affected with this aggressive type of leukaemia.